Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
Nuvation Bio gets $250M total funding for taletrectinib commercialization & pipeline; Syros to delist from Nasdaq on March 20 after January compliance warning ...
US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback